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We have reported that normal human salivary gland-derived
epithelial cells exclusively express keratinocyte growth factor re-
ceptor (KGFR). In the process of malignant transformation of
human salivary gland tumors, KGFR gene expression disappeared
concomitantly with the de novo expression of the fibroblast
growth factor receptor 1 (FGFR1) and FGFR4 genes. In the present
study, we introduced wild-type KGFR cDNA or chimeric KGFRy
FGFR1 cDNA, which encoded the extracellular domain of KGFR and
the intracellular domain of FGFR1, into the HSY human salivary
adenocarcinoma cell line. The KGFR tyrosine kinase suppressed the
activity of FGF receptor substrate 2 (FRS2) and inhibited the growth
of HSY by inducing differentiation and apoptosis in vitro and in
vivo. Our results provided significant insight into the mechanism of
KGFR tumor suppression and suggest that KGFR gene therapy
might be a viable method of inhibiting human salivary adenocar-
cinoma growth.
Keratinocyte growth factor (KGFyFGF7) is a member of thefibroblast growth factor (FGF) family (1). Its activity is
largely restricted to epithelial cells, which express the KGF
receptor (KGFR), a transmembrane tyrosine kinase encoded by
the IIIb splice variant of FGFR2 (FGFR2-IIIb) (2, 3). KGFR
binds KGF and FGF-1 with high affinity. In contrast, FGFR2-
IIIc, another splice variant of FGFR2, binds FGF-1 and FGF-2,
but not KGF (3, 4). Analysis of KGF and KGFR expression
during embryonic development, including that of mammary
glands, has provided evidence that KGF is an important mes-
enchymal mediator of epithelial growth and differentiation. In
normal human skin, KGFR immunostaining localizes to the
suprabasal layers (5, 6). The lack of KGFR in basal cell pro-
genitors in skin suggests that KGFR might regulate keratinocyte
differentiation (7).
Malignant salivary tumors are highly aggressive neoplasms
that readily invade adjacent tissues and metastasize to distant
organs at early stages of the disease. Malignant salivary tumors
exhibit enhanced expression of both FGF-1 and FGF-2 com-
pared with normal salivary gland (8). FGF-1 and FGF-2 can act
in an autocrine manner to stimulate the proliferation of salivary
adenocarcinoma cells (8, 9). Normal salivary gland epithelial
cells and benign salivary gland tumors exclusively express the
KGFR gene. During the malignant transformation of salivary
gland epithelial cells, the expression of the KGFR gene is
abolished, whereas the FGFR1-IIIc and FGFR4 genes are
activated (10). The exclusive expression of the KGFR gene in
both normal and premalignant salivary epithelial cells correlates
well with the slow-growing and differentiated phenotype of
premalignant tumors. In contrast, the loss of the KGFR gene and
the expression of both the FGFR1 gene and its specific ligand
FGF-2 in malignant tumor cells are associated with the emer-
gence of the malignant phenotype. Thus, the loss of normal
KGFR gene function may promote tumorigenicity, whereas
KGFR may function to suppress human salivary adenocarcinomas.
The Ras-MAP kinase signaling pathway plays an important
role in signaling via FGFRs (11, 12). It is now well established
that the lipid-anchored docking protein FGF receptor substrate
2 (FRS2) links FGFR molecules with the Ras-MAP kinase
signaling pathway by forming a complex with the N-terminal
SH2 domain of the protein tyrosine phosphatase Shp2 and the
adaptor protein Grb2. Blocking FRS2 signaling results in weak
Ras-MAP kinase phosphorylation (13, 14). In the present study,
we found that the wild-type KGFR gene transferred into HSY
human salivary adenocarcinoma cells caused a decreased level of
tyrosine-phosphorylated activity of FRS2, resulting in apoptosis
and differentiation in vitro and in vivo. Our data provide insight
into the mechanism of KGFR tumor suppression.
Materials and Methods
Cell Culture and Recombinant DNA Constructs. Normal salivary
gland-derived epithelial (SGE) cells were isolated from human
submandibular glands and cultured in serum-free medium as
described (15). The human salivary adenocarcinoma cell line
HSY (16) was kindly provided by Professor Mitsunobu Sato
(Second Department of Oral and Maxillofacial Surgery, To-
kushima University School of Dentistry, Tokushima, Japan).
HSY was maintained in RD medium (RPMI 1640 mediumy
DMEM, 1:1) supplemented with 5% calf serum as described
(10).
KGFR carrying full-length FGFR2-IIIb cDNA and chimeric
KGFRyFGFR1 carrying the extracellular domain of KGFR and
the intracellular domain of FGFR1 were cloned into mammalian
expression vector pcDNA3.1yzeo (Invitrogen) as described (17).
For transfection, 60% confluent HSY cells were preincubated
with serum- and antibiotic-free RD medium for 2 h, then
transfected with wild-type KGFR or chimeric KGFRyFGFR1
cDNAs by a liposome-mediated method with the use of Lipo-
fectamine Plus Reagent (GIBCOyBRL and Life Technologies,
Rockville, MD). As a control, pcDNA3.1yzeo bearing no cDNA
insert was introduced. The cells were then selected with 400
mgyml of Zeocin (Invitrogen) for 2 weeks, and the colonies of
cells emerging from the selection medium were isolated and
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further selected by RRA with 125I-KGF as described (18).
KGFR-overexpressing HSY cells were designated HSYR2-IIIb,
KGFRyFGFR1-overexpressing HSY cells were designated
HSYR2yR1, and the control transfectants were designated
HSYzeo.
Cell Proliferation Assay. For the study of population growth rates,
HSYzeo, HSYR2yR1, and HSYR2-IIIb cells (1 3 104 cells per
well) were seeded into type I collagen (Cell Matrix type I-A;
Nitta Gelatin Co., Osaka, Japan)-coated 24-well culture plates,
respectively, in serum-free RD medium containing 10 mgyml
bovine insulin, 5 mgyml human transferrin, 10 mM mercapto-
ethanol, 10 mM 2-aminoethanol, and 10 nM sodium selenite
(RD5F) (19). Cell numbers were counted daily for 6 days.
To evaluate the effect of FGF on the growth of the transfec-
tants in serum-free culture, HSYzeo, HSYR2yR1, and HSYR2-
IIIb cells (3 3 103 cells per well) were seeded in RD5F and
incubated with the indicated concentrations of FGF-1, FGF-2, or
KGF for 5 days. FGF-1 was purified from bovine brain, and rat
recombinant KGF was prepared as described (20, 21). Human
recombinant FGF-2 was purchased from Upstate Biotechnology
(Lake Placid, NY). Cell numbers were measured with a Coulter
Counter (Coulter Electronics, Hialeah, FL).
Immunocytochemical Analysis. To determine whether transfec-
tants were undergoing differentiation, the salivary gland differ-
entiation markers a-amylase and lactoferrin were analyzed
immunocytochemically. Briefly, the cells were cultured in RD5F
without KGF on Lab-Tek II chamber slides (Nalgen Nunc
International, Naperville, IL) for 2 days, then the cells were fixed
with freshly prepared 2% paraformaldehyde for 30 min. After
blocking with 10% normal goat serum for 30 min, the cells were
incubated with rabbit anti-amylase antibody (Dako) diluted by
1:100 or rabbit anti-lactoferrin antibody (Dako) diluted by 1:100.
Immunodetection of the antigens was performed with the Elite
Avidin-Biotin-Immunoperoxidase System (Vector Laborato-
ries) according to the manufacturer’s instructions. Staining of
the cells was graded as follows: 0–11, negative to indeterminate
cell staining; 21, weak but clearly positive cell staining; 31,
strong cell staining.
Detection of Apoptotic DNA Fragmentation. The cells (104 cells per
milliliter) were cultured in serum-free RD5F with 20 ngyml KGF
on 10 cm2 dish (10 dishes per experiment point). DNA was
extracted from the adherent and floating cells every day for 7
days as described (22). DNA samples were electrophoresed on
2% agarose gel and visualized by ethidium bromide staining to
detect DNA fragmentation.
Tumor Cell Implantation and Histochemical Analysis. One hundred
and five female athymic mice (BALByc, AnNCrj-nuyr, 5 weeks
old) were used for this study. The research protocol was ap-
proved, and mice were maintained in accordance with institu-
tional guidelines of the Hiroshima University Animal Care and
Use Committee. Five mice per clone were used per experiment.
In each experiment, 35 mice were used. The cells (2 3 106)
suspended in 100 ml of PBS were injected s.c. in the lateral back
region. Tumor volume (V) was measured twice a week, accord-
ing to the formula V 5 1y2 3 length 3 width2). Mice were killed
by cervical dislocation 4 weeks after inoculation. For histochem-
ical analysis, the tumor tissues were fixed in freshly prepared 4%
paraformaldehyde and embedded in paraffin. Tissues were
sectioned and stained with hematoxylinyeosin.
Terminal Deoxynucleotidyl Transferase-Mediated dUTP-Biotin Nick-
End Labeling (TUNEL) Assay. Paraffin sections (4–6 mm) of tumor
specimen were digested with proteinase K (20 mgyml) for 5 min
at 37°C and then incubated with terminal deoxynucleotidyl
transferase enzyme (Wako Pure Chemical, Osaka) for 60 min at
37°C. After being treated with 3% H2O2 for 5 min at room
temperature, the sections were incubated with peroxidase-
conjugated antibody (Wako Pure Chemical, Osaka) for 60 min
at 37°C. The reaction was visualized with diaminobenzidine–
H2O2 substrate.
Analysis of FRS2 Phosphorylation. The cells were nutrition-starved
for 24 h and then incubated with 20 ngyml of FGF-1, FGF-2, or
KGF for 5 min at 37°C. The cells were washed three times with
cold PBS containing 1 mM Na3VO4 and lysed with lysis buffer
(50 mM Hepesy1% Triton X-100y10% glyceroly150 mM NaCly
100 mM NaFy1.5 mM MgCl2y1 mM EGTAy1 mM Na3VO4y1
mM phenylmethylsulfonyl f luoridey10 mg/ml aprotinin). The
sonicated and clarified cell lysates (500 mg per sample) were
immunoprecipitated with 3 mg of rabbit anti-Grb2 antibody
(Transduction Laboratories, Lexington, KY) overnight at 4°C,
and then the antigen–antibody complexes were recovered by a
2-h incubation with protein A–Sepharose CL-4B (Amersham
Pharmacia) at 4°C. The immunoprecipitated samples were elec-
trophoresed on 7.5% SDSypolyacryamide gel under reducing
conditions and transferred to Immobilon-P membrane (Milli-
pore). The membrane was incubated with a 1:1,000 dilution of
anti-phosphotyrosine monoclonal antibody 4G10 (Upstate Bio-
technology) or a 1:1,000 dilution of goat anti-FRS2 antibody
(Santa Cruz Technology) overnight at 4°C. Immunodetection of
the antigen was performed with the 5-bromo-4-chloro-3-indolyl
phosphateynitroblue tetrazolium Membrane Phosphatase Sub-
strate System (Kirkegaard & Perry Laboratories) according to
the manufacturer’s instructions.
Statistical Analysis. Immunocytochemical results were analyzed
with the use of contingency tables and the Kruskal–Wallis rank
test. ANOVA and Tukey’s test were used for other data.
Significance was defined as P , 0.05. The statistical software
used was STATVIEW 5.0 (SAS Institute, Cary, NC).
Results
Differential Growth of Transfectants. Among 58 Zeocin-resistant
HSYR2-IIIb clones and 50 Zeocin-resistant HSYR2yR1 clones,
seven HSYR2-IIIb clones and seven HSYR2yR1 clones were
selected for analysis because they exhibited higher KGFR num-
bers (Table 1). The transfected cell line HSYR2-IIIb prolifer-
ated with a doubling time of 52 h (SD 1.9), whereas HSYzeo and
HSYR2yR1 proliferated with doubling times of 18 h and 19 h
(SD 1.2 and 1.7), respectively (Table 1). The growth rate of
HSYR2-IIIb cells was significantly lower than those of HSYzeo
and HSYR2yR1 (P , 0.001; Fig. 1). FGF-1 at 20 ngyml showed
a 4-fold stimulation of HSYzeo growth and a 2.5-fold stimulation
of HSYR2yR1 growth in serum-free culture (Fig. 2A). FGF-2 at
20 ngyml showed a 4.8-fold stimulation of HSYzeo and a 2.5-fold
stimulation of HSYR2yR1 growth in serum-free culture (Fig.
2B). The growth of HSYR2-IIIb was not stimulated by either
FGF-1 or FGF-2 (Fig. 2). Although HSYR2yR1 and HSYR2-
IIIb expressed KGFR, KGF did not have a mitogenic effect on
HSYR2yR1 or HSYR2-IIIb.
Cellular Differentiation and Apoptosis in HSYR2-IIIb in Vitro. By
immunocytochemical analysis HSYzeo and HSYR2yR1 cells
exhibited negative to weakly positive staining for a-amylase and
lactoferrin, whereas HSYR2-IIIb cells were strongly positive for
both a-amylase and lactoferrin in the cytoplasm and perinuclear
regions (Fig. 3).
HSYR2-IIIb cells detached from the culture plates over a
4-day serum-free culture period with 20 ngyml KGF and even-
tually died. By trypan blue dye exclusion, ’10% of the cells
detached and died on day 2, 15% on day 3, 50% on day 4, and
90% on day 7. TUNEL positive cells were observed in HSYR2-
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IIIb, although no TUNEL positive cells were detected in
HSYzeo or HSYR2yR1. On the third day of culture with KGF,
15% of HSYR2-IIIb was positive for TUNEL staining, and 70%
were positive for TUNEL staining on day 7. Compaction and
margination of nuclear chromatin, condensation of cytoplasm,
and convolution of nuclear and cell outlines were observed in
cultured HSYR2-IIIb (data not shown). No detectable fragmen-
tation was observed in DNA derived from HSYzeo and
HSYR2yR1 cultured with KGF (20 ngyml) for 7 days. On the
other hand, DNA laddering was observed in DNA derived from
HSYR2-IIIb cultured with KGF (20 ngyml) for 4 days, and it
increased markedly over a 7-day period (Fig. 4).
Differentiation and Apoptosis in HSYR2-IIIb in Vivo. Because KGFR
was able to inhibit the growth of HSY in vitro, we attempted to
determine whether KGFR expression suppressed the tumorige-
nicity of HSY cells. There was no significant difference between
the tumor growth of HSYzeo and HSYR2yR1 (P . 0.05). In
contrast, there was a significant reduction in growth rate of
HSYR2-IIIb-derived tumors compared with that of HSYzeo-
and HSYR2yR1-derived tumors (P , 0.001, Fig. 5A, Table 1),
and three of seven HSYR2-IIIb clones lost their tumorigenicity
(Table 1). The HSYR2-IIIb-derived tumors were much smaller,
softer, and paler in comparison with HSYzeo-derived tumors;
Table 1. The KGFR number, proliferative activity, and
tumorigenicity of transfectants
Transfectant
KGFR
number*
Doubling time
in vitro, h†
Tumor
incidence
HSYR2-IIIb
c1.1A 0.8 50.6 6 2.3 5y5
c1.2A 1.2 50.5 6 2.5 0y5
c1.3A 1.6 51.8 6 1.9 5y5
c1.4A 1.8 51.8 6 2.3 5y5
c1.5A 2.8 51.9 6 2.9 0y5
c1.6A 3.3 52.5 6 1.6 5y5
c1.7A 5.7 52.9 6 1.0 0y5
HSYR2/R1
c1.1B 0.8 19.7 6 1.4 5y5
c1.2B 0.9 18.6 6 1.9 5y5
c1.3B 0.9 19.2 6 2.7 5y5
c1.4B 1.2 18.1 6 1.5 5y5
c1.5B 1.9 19.7 6 2.8 5y5
c1.6B 2.2 19.3 6 1.5 5y5
c1.7B 4.2 18.4 6 0.4 5y5
HSYzeo
c1.1C — 18.0 6 1.2 5y5
c1.2C — 17.8 6 1.5 5y5
c1.3C — 18.6 6 1.1 5y5
c1.4C — 18.6 6 1.2 5y5
c1.5C — 19.1 6 2.0 5y5
c1.6C — 18.8 6 0.5 5y5
c1.7C — 17.5 6 1.3 5y5
*KGF receptor numbers (31025).
†Mean 6 SD.
Fig. 1. Population growth kinetics of the transfectants in serum-free culture.
The cells (1 3 104 cells per well) were seeded in type I collagen-coated 24-well
culture plates, and they were counted daily for 6 days. HSYzeo (h) and
HSYR2yR1 () had doubling times of 18 h and 19 h, respectively, whereas
HSYR2-IIIb (E) proliferated with a doubling time of 52 h. Three independent
experiments were performed with duplicate wells. Each point indicates a
mean 6 SD.
Fig. 2. The effects of FGF-1 and FGF-2 on the growth of the transfectants in
serum-free culture. The cells (3 3 103 cells per well) were seeded in type I
collagen-coated 24-well culture plates in RD5F and incubated with the indi-
cated concentrations of FGF-1 or FGF-2 for 5 days. (A) FGF-1 at 20 ngyml
showed a 4-fold stimulation of HSYzeo growth (h) and a 2.5-fold stimulation
of HSYR2yR1 growth (). (B) FGF-2 at 20 ngyml showed a 4.8-fold stimulation
of HSYzeo growth and a 2.5-fold stimulation of HSYR2yR1 growth. Neither
FGF-1 nor FGF-2 stimulated the growth of HSYR2-IIIb (E). Mean values of
duplicate wells from three independent experiments are shown.
Fig. 3. Immunoperoxidase staining for a-amylase and lactoferrin. HSYzeo
and HSYR2yR1 exhibited weakly positive staining for a-amylase (A and C) and
lactoferrin (B and D). HSYR2-IIIb showed intensive positive staining for a-
amylase (E) and lactoferrin (F) in the cytoplasm and perinuclear regions. The
cells shown are representative of seven clones each.
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they exhibited rounded structures with smooth surfaces; and they
were well encapsulated and demarcated from the surrounding
connective tissues. HSYzeo- and HSYR2yR1-derived tumors
had an irregular rounded appearance with lobulated or multi-
nodular surfaces. The connective tissue, which is abundant in
vascularization, did not completely encapsulate the tumors (data
not shown). Histologically, tumors developed from HSYR2-IIIb
exhibited prominent duct-like and acinar-like structures sur-
rounded by stromal cells (Fig. 5B1). Furthermore, in some
undifferentiated areas, DNA fragmentation and apoptotic bod-
ies were observed in the nuclei of HSYR2-IIIb-derived tumors
(Fig. 5B2). HSYzeo- and HSYR2yR1-derived tumors exhibited
typical adenocarcinomas with a solid and trabecular pattern (Fig.
5 B3 and B4).
Differential Kinase Phosphorylation. As FRS2 is essential for FGF-
induced DNA synthesis (13), we assessed the phosphorylation
state of FRS2 after FGF stimulation in different transfectants
and SGE cells. FRS2 was identified as a tyrosine-phosphorylated
protein in HSYzeo and HSYR2yR1 cells stimulated with FGF1
and FGF2, but not in HSYR2-IIIb and SGE cells (Fig. 6). On
stimulation with FGF-1 and FGF-2, p38 MAP kinase was
strongly activated in HSYzeo and HSYR2yR1 cells, but not in
HSYR2-IIIb or SGE (data not shown). Moreover, the prolifer-
ation of HSYzeo and HSYR2yR1 was inhibited significantly in
the presence of the specific p38 MAP kinase inhibitor SB203580
(data not shown).
Discussion
In the present study, we have demonstrated that the wild-type
KGFR gene transferred into HSY human salivary adenocarci-
noma cells induced differentiation and apoptosis, while sup-
pressing tumor cell growth in vitro and inhibiting tumor growth
in athymic mice. Apoptosis, or programmed cell death, is a
fundamental process in organ development and tissue homeosta-
sis in complex organisms (23). The induction of apoptosis has
been widely used as an approach to cancer therapy (24). The
morphological hallmarks of apoptosis, including membrane
blebbing, volume loss, nuclear condensation, and DNA frag-
mentation, were all observed when a wild-type KGFR gene was
transfected into HSY salivary adenocarcinoma cells. The apo-
ptosis of HSYR2-IIIb cells was observed during a 7-day culture
in KGF. Furthermore, endogenous DNA fragmentation and
apoptotic bodies were observed in HSYR2-IIIb-derived tumors
in athymic mice. These results describe a mechanism of blocking
tumor growth in which restoration of KGFR tyrosine kinase
activity in HSY cells induces apoptosis on stimulation by its
ligand KGF.
a-Amylase and lactoferrin are major secretory products of
human salivary glands that serve as markers of acinar cell and
ductal cell differentiation, respectively (25–27). Immunocyto-
chemical analysis indicated that the expression level of a-
amylase and lactoferrin in HSYR2-IIIb was much higher than
that in HSYzeo and HSYR2yR1 even without KGF. Histological
examination revealed that predominant duct-like, acinar-like
structures and apoptotic cells were always observed closely
opposed to stromal cells in HSYR2-IIIb-derived tumors. These
results suggest that the tyrosine kinase of KGFR is very impor-
tant for cellular differentiation and that the communication
between stromal cells and epithelial cells was involved in the
induction of cellular differentiation.
The growth of HSYzeo and HSYR2yR1 was stimulated by
either FGF-1 or FGF-2, but not by KGF. In contrast, the growth
of HSYR2-IIIb was not stimulated by FGF-1, FGF-2, or KGF.
We found that FGFR1 and FGFR4 were still expressed in
HSYR2-IIIb by reverse transcription–PCR analysis (data not
Fig. 4. Detection of DNA fragmentation in HSYzeo (A), HSYR2yR1 (B), and
HSYR2-IIIb (C). The cells were incubated with KGF (20 ngyml) for 4 days (lanes
1, 3, and 5) or 7 days (lanes 2, 4, and 6).
Fig. 5. Analysis of tumors formed in nude mice. (A) The tumorigenicity of
HSYzeo, HSYR2yR1, and HSYR2-IIIb. There was no significant difference be-
tween the tumor growth of HSYzeo (h) and HSYR2yR1 () (P . 0.05). In
contrast, there was a significant reduction in growth rate of HSYR2-IIIb-
derived tumors (E) as compared with those of HSYzeo- and HSYR2yR1-derived
tumors (P , 0.001). For each group, the mean 6 SE was plotted. (B1) Tumors
developed from HSYR2-IIIb exhibited predominant gland-like and acinar-like
structures surrounded by stromal cells (arrowhead). In some areas, apoptotic
bodies were observed in the nuclei of the tumor cells (circled) (original
magnification: 3100). (B2) On TUNEL examination, tissue section of HSYR2-
IIIb-derived tumor showed positive signals in tumor cells (arrowhead) (original
magnification: 3200). The histological appearances of HSYR2yR1-derived (B3)
and HSYzeo-derived (B4) tumors exhibited typical adenocarcinomas with a
solid and trabecular pattern (original magnification: 3100).
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shown). How does KGFR tyrosine kinase alter the signaling of
FGF-1 and FGF-2 to inhibit tumor growth? Like many other
growth factor receptors, KGFR, when overexpressed, may be
easily autophosphorylated in the absence of ligand (28, 29). Our
results showed that the differentiation and apoptosis of HSYR2-
IIIb cells occurred even in the absence of KGF and were further
accelerated in the presence of KGF. Stimulation of cell prolif-
eration and differentiation by FGF receptors depends on the
Ras-MAP kinase signal pathway (30, 31). FRS2 plays an impor-
tant role in linking FGF with Ras-MAP kinase signaling. In
response to FGF stimulation, FGF receptors bind to Grb2 to
become tyrosine-phosphorylated by FRS2. It has been shown
that FGF-induced DNA synthesis can be inhibited by microin-
jection of anti-FRS2 antibody (13). Moreover, an FRS2 mutant
impaired Grb2 binding and failed to induce neuronal differen-
tiation of PC12 cells (14). In the present study, either FRS2 or
p38 MAP kinase was identified as a phosphorylated protein in
HSYzeo and HSYR2yR1, but not in HSYR2-IIIb or SGE cells
on stimulation by FGFs. These results demonstrated that the
tyrosine kinase of KGFR suppresses the phosphorylation of
FRS2 and blocks p38 MAP kinase signaling. Moreover, the
specific p38 MAP kinase inhibitor SB203580 inhibited the
proliferation of HSYzeo and HSYR2yR1, suggesting that the
blocking of p38 MAP kinase may be one mechanism by which
the restoration of KGFR tyrosine kinase inhibits adenocarci-
noma cell growth.
We have reported that FGF-1 and KGF stimulated the growth
of SGE cells (10); however, tyrosine phosphorylation of FRS2
was not observed in SGE. The result implies that FGF stimulates
proliferation of normal epithelial cells and malignant cells by
distinct signaling pathways.
The progressive loss of KGFR expression has been implicated
in the malignant progression of many tumors, including human
bladder tumors (32) and prostate tumors (33). It has also been
demonstrated that restoration of KGFR tyrosine kinase induced
the differentiation of malignant cells and inhibited the growth of
human bladder carcinomas and malignant rat prostate carcino-
mas (32, 34). However, the mechanism by which the KGFR gene
inhibits malignant cell growth was not elucidated. Our findings
demonstrate that the restoration of KGFR tyrosine kinase in
human adenocarcinoma cells caused decreased levels of FRS2
phosphorylation and led to induction of apoptosis and differ-
entiation. These results suggest that KGFR gene therapy might
be a viable approach to inhibiting the growth of salivary
adenocarcinomas.
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Fig. 6. FGF-stimulated phosphorylation of FRS2. The cell lysates extracted
from SGE, HSYzeo, HSYR2yR1, and HSYR2-IIIb were immunoprecipitated with
anti-Grb2 antibody and were blotted with anti-phosphotyrosine antibody or
anti-FRS2 antibody. Closed arrowheads indicate the position of the phosphor-
ylated form of FRS2, and open arrowheads indicate the position of the
unphosphorylated forms of FRS2. Lane 1: Control; lane 2: FGF-1 stimulated;
lane 3: FGF-2 stimulated; lane 4: KGF stimulated. Data represent the results of
clone 7A and clone 7B, as other clones gave essentially the same results.
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